Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Holding ABEO?
Track your performance easily
Earnings Data
Report Date
Mar 24, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.34Last Year’s EPS
-$0.59Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -6.56%
|Next Earnings Date:Mar 24, 2025
Earnings Call Sentiment|Neutral
The earnings call demonstrated significant progress towards the approval and commercialization of pz-cel, with strategic steps in place for launch and financial stability. However, there remain challenges related to manufacturing capacity and ongoing financial losses.Company Guidance
In the third quarter 2024 earnings call for Abeona Therapeutics, several key metrics and updates were shared regarding their lead product candidate, prademagene zamikeracel (pz-cel). The company successfully resubmitted its biologics license application (BLA) to the FDA, which was accepted with a PDUFA date set for April 29, 2025. They have a manufacturing capacity of up to 10 patient runs per month, with plans for expansion. Commercialization efforts include building a team of about 20 members and targeting five initial EB centers across the U.S. to facilitate patient access. Financially, Abeona reported cash and equivalents of $110 million as of September 30, 2024, with a net loss of $30.3 million for the quarter, including a $15.2 million loss from warrant liabilities. The company anticipates having sufficient financial resources to fund operations into 2026, without accounting for potential revenue from pz-cel sales or a priority review voucher, which could be valued at over $150 million.Resubmission of BLA for pz-cel Accepted
The FDA accepted the resubmission for review and set a PDUFA date of April 29, 2025, indicating progress towards potential approval.
New U.S. Patents Issued
A new U.S. patent for pz-cel was issued with an expiration date of 2037, and another patent will issue relating to its packaging and transport system, expiring in 2040.
Commercial Launch Preparations
A strong commercialization team has been assembled, and 5 EB centers are targeted for launch. Approximately 750 pz-cel-eligible U.S. RDEB patients have been identified.
Favorable Medicare Reimbursement
CMS granted a product-specific procedure code and favorable MS-DRG 018 assignment, supporting reimbursement for Medicare RDEB patients.
Financial Position
Cash resources of $110 million as of September 30, 2024, expected to fund operations into 2026.
---
ABEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $6.10 | $5.95 | -2.46% |
| Aug 12, 2024 | $4.42 | $4.95 | +11.99% |
| May 15, 2024 | $4.20 | $4.71 | +12.14% |
| Mar 18, 2024 | $8.63 | $6.99 | -19.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Abeona Therapeutics (ABEO) report earnings?
Abeona Therapeutics (ABEO) is schdueled to report earning on Mar 24, 2025, TBA Not Confirmed.
What is Abeona Therapeutics (ABEO) earnings time?
Abeona Therapeutics (ABEO) earnings time is at Mar 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABEO EPS forecast?
ABEO EPS forecast for the fiscal quarter 2024 (Q4) is -$0.34.
---